Fiche publication
Date publication
février 2016
Journal
Progress in neuro-psychopharmacology & biological psychiatry
Auteurs
Membres identifiés du Cancéropôle Est :
Pr TROJAK Benoît
,
Dr LUTZ Pierre-Eric
Tous les auteurs :
Lalanne L, Lutz PE, Trojak B, Lang JP, Kieffer BL, Bacon E
Lien Pubmed
Résumé
Many epidemiological studies have revealed a frequent co-occurrence of psychiatric and substance use disorders. The term used in the literature to refer to this co-occurrence is dual diagnosis. The high prevalence of dual diagnosis has led physicians to observe the effects of medication prescribed to treat psychiatric disorders on the co-occurring substance use disorder and vice versa. The concept of medications between psychiatric and addictive disorders stems from these clinical observations, alongside which, however, it has developed from the observation that both psychiatric and substance use disorders share common neurobiological pathways and trigger common cognitive disorders. This has led researchers to develop medications on the basis of neurobiological and cognitive rationales.
Mots clés
Animals, Diagnosis, Dual (Psychiatry), Humans, Psychotropic Drugs, therapeutic use, Substance-Related Disorders, complications
Référence
Prog. Neuropsychopharmacol. Biol. Psychiatry. 2016 Feb 4;65:215-23
